

December 8, 2010

BioSystem Development and Agilent Technologies Collaborate to Bring Precision and High-Throughput to AssayMAP® Micro-scale Chromatography

Madison, WI (USA) & Santa Clara, CA (USA) - BioSystem Development and Agilent Technologies Inc. (NYSE: A) announced a collaborative agreement to implement BioSystem Development's patented technology on the established Agilent Bravo automated liquid handling platform. BioSystem Development is a privately held life sciences analytics company and creator of AssayMAP® high-throughput micro-chromatography technology. The combined technologies will produce for the first time true chromatography separations on disposable, 5 µl packed-bed columns in a 96-channel SBS microplate format.

The collaboration creates a versatile integrated solution for protein sample preparation and processing. The new open-platform instrument combines the Agilent Bravo with 96AM head with AssayMAP cartridges that are packed with any chromatographic resin or immobilized enzyme. The new instrument enables a broad range of standard analytical workflows to be rapidly reformatted to this precision, high-throughput platform.

"Customers are challenged with delivering large numbers of high-quality samples to our analytical platforms," said Nitin Sood, general manager of Agilent's Automation Solutions Division. "The Bravo liquid handling platform for the AssayMAP system enables our customers to reproducibly provide high-purity, highly parallelized samples to their multiple analytics platforms in formats they can use right away. We believe that the combined strength of Agilent's automation and the AssayMAP technology will improve biologics discovery and development, reducing cycle times and improving the quality of results."

The Bravo with 96AM head instrument will be launched at the Lab Automation meeting in January. Agilent will become a single point of contact for complete protein purification solutions built on the Bravo and AssayMAP technologies. Agilent will continue to expand the AssayMAP content portfolio leveraging extensive expertise in sample preparation applications, and BioSystem Development will focus on bringing new chemistries and content partners into the platform under their AssayMAP Alliance program.

"Agilent's innovative automation solutions are critical to the development of the AssayMAP platform," said Scott Fulton, founder and CEO of BioSystem Development, LLC. "Agilent is enabling the evolution of AssayMAP from simple 'bind-and-elute' workflows to true high-precision chromatography on an established fully automated platform. We look forward to Agilent helping us to move well beyond the bioprocess development market that is our current focus."

About BioSystem Development

BioSystem Development, established in 2002, creates, manufactures and markets tools and products to meet the critical and growing analytical needs of biopharmaceutical development. The company's patented AssayMAP platform, based on disposable micro-chromatography cartridges and automation, enables high throughput solutions for bioprocess development, biomarkers and general life science research that reduce development time and increase efficiency. AssayMAP® is patented technology of BioSystem Development. AssayMAP® is a registered trademark of BioSystem Development.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of \$5.4 billion in fiscal 2010. Information about Agilent is available at <http://www.agilent.com>.

For additional information, please contact:

Scott Fulton
Founder and CEO
BioSystem Development, LLC
scott.fulton@biosystemdevelopment.com
608 345-8297

www.assaymap.com

Eric Endicott
Life Sciences & Chemical Analysis
Agilent Technologies, Inc.
eric_endicott@agilent.com
+408 553 2005

www.agilent.com